title: Antifibrotic activity of hyaluronidase immobilized on polyethylenoxide under conditions of bleomycin-induced pneumofibrosis.
abstract: Hyaluronidase immobilized on polyethylenoxide obtained by electron bean synthesis was administered intranasally and intravenously to C57Bl/6 mice after intratracheal bleomycin and the enzyme effects on the development of pneumofibrosis in animals were studied. Intranasal immobilized hyaluronidase prevented connective tissue growth in the lungs exposed to bleomycin and virtually did not modulate the infiltration of the alveolar and alveolar duct interstitium by inflammatory cells (lymphocytes, macrophages, neutrophils, plasma cells). The antifibrotic effect developed sooner after intranasal inoculation of immobilized hyaluronidase and was more pronounced than after intranasal native hyaluronidase. Intravenous injection of immobilized hyaluronidase did not modify the inflammatory process and deposition of collagen fibrils in the lung parenchyma in pneumofibrosis.
authors.affiliation: Institute of Pharmacology, Siberian Division of the Russian Academy of Medical Sciences, Tomsk, Russia.
authors.forename: A M
authors.initials: AM
authors.lastname: Dygai
authors.forename: E G
authors.initials: EG
authors.lastname: Skurikhin
authors.forename: N N
authors.initials: NN
authors.lastname: Ermakova
authors.forename: O V
authors.initials: OV
authors.lastname: Pershina
authors.forename: V A
authors.initials: VA
authors.lastname: Krupin
authors.forename: A M
authors.initials: AM
authors.lastname: Reztsova
authors.forename: L A
authors.initials: LA
authors.lastname: Ermolaeva
authors.forename: E S
authors.initials: ES
authors.lastname: Khmelevskaya
authors.forename: A V
authors.initials: AV
authors.lastname: Artamonov
authors.forename: A A
authors.initials: AA
authors.lastname: Bekarev
authors.forename: P G
authors.initials: PG
authors.lastname: Madonov
authors.forename: D N
authors.initials: DN
authors.lastname: Kinsht
mesh_terms: D000818:Animals; D001761:Bleomycin; D003238:Connective Tissue / Q000187:drug effects*; D003239:Connective Tissue Cells / Q000187:drug effects; D004800:Enzymes, Immobilized / Q000627:therapeutic use*; D006820:Hyaluronic Acid / Q000378:metabolism; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy*; D007958:Leukocyte Count; D008168:Lung / Q000187:drug effects / Q000473:pathology; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009504:Neutrophils / Q000276:immunology; D010950:Plasma Cells / Q000276:immunology; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D004800:Enzymes, Immobilized; D001761:Bleomycin; D011092:Polyethylene Glycols; D006820:Hyaluronic Acid; D006821:Hyaluronoglucosaminidase